Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Pancreatitis

Conditions

Chronic Pancreatitis

Trial Timeline

Feb 1, 2009 → Mar 1, 2012

About Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium

Nexium (esomeprazole magnesium) + Placebo to Nexium + Viokase 16 (pancrelipase) + Nexium + Viokase 16 + placebo to Nexium is a phase 1 stage product being developed by AstraZeneca for Chronic Pancreatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01142128. Target conditions include Chronic Pancreatitis.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Pancreatitis were approved

Approved (20) Terminated (3) Active (0)
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
alefaceptAstellas PharmaApproved
AlefaceptAstellas PharmaApproved
lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
6
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01142128Phase 1Terminated

Competing Products

20 competing products in Chronic Pancreatitis

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25